In two patients with metastatic breast cancer harboring different germline PTEN mutations, treatment with capivasertib led to durable complete tumor responses, suggesting that AKT inhibitors provide a rational option for cancer patients harboring germline PTEN mutations [8]. Here, AKT1 is linked to neoplasm.